PTO/SB/08a (08-03)
Approved for use through 97/31/2006, ONB 0651-0201
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unfers it contains a valid OMS control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10802223				
Filing Date		2004-03-17				
First Named Inventor	Martin	John Founds				
Art Unit		3782				
Examiner Name	Jes F	. Pascua				
Attorney Docket Numb	er	198/41728/Case 508				

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date Name of Patentee or Applicant			Releva	,Columns,Lines who ant Passages or Rel s Appear		
	1	6063226		2000-05	i-16	FOSTER ET A	L			
If you wish	h to a	ı dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant Re			Columns,Lines whe ant Passages or Rel s Appear	
	1									
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add	
				FOREIG	SN PA1	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	Te
	1	83 08 743	DE			1983-07-14	HELL RUDOLF DR ING GMBH			
	2	1 000 021	NL.			1995-05-18	STRONGHOLD PA GROUP BV	VPER		
	3	72 38 855	DE			1973-01-25	BRUGMANN DIRK			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10802223			
iling Date		2004-03-17			
irst Named Inventor Martin		John Founds			
Art Unit		3782			
xaminer Name Jes F.		Pascua			
Attorney Docket Numb	er	198/41728/Case 508			

If you wish	h to a	dd add	ditio	onal I	oreign	Pater	nt Do	cume	ent ci	tation	infor	nation	please	e click th	e Add	button	Add			
							NON	I-PA	TENT	LITE	RAT	JRE D	ocul	MENTS			Remo	ve		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city anotic country where published.									Т5										
	1 Entended European Search Report dated August 13, 2004 which issued in connection with corresponding European Application No. 04 07 5945.																			
If you wish	h to a	dd add	ditio	onal r	on-pat	ent lite	eratu	ire do	ocume	ent cit	tation	inform	ation p	lease cl	ick the	Add b	utton	Add		
									EXA	MINE	R SIG	NATU	RE							
Examiner	Signa	ture	Τ											Date C	onside	red				
*EVAMIN	CD: 1-	itial if				deres	4	- att-a		-1-1	ation i	in			- MDE	000	Deeu II		raugh a	

1 See Kind Codes of USPTO Patent Documents at www.ISPTO.000/c of MPE 90104. 2 Enter office that issued the document, by the hor-letter code (WIPO Standard ST3.) 2 For Jungsness petant counters, the includes not not be year of the insper or the protect the sest and runner of the patent of the pat

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10802223		
Filing Date		2004-03-17		
First Named Inventor Martin		John Founds		
Art Unit		3782		
Examiner Name Jes F.		Pascua		
Attorney Docket Numb	er	198/41728/Case 508		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make th	e appropriate selection(s):
---------------	----------	---------------------	-----------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.57(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.					
Signature	/James R. Foley/	Date (YYYY-MM-DD)	2006-12-11		
Name/Print	James R Foley	Registration Number	39 979		

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiler. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.